CN113286803A - S-抗原转运抑制寡核苷酸聚合物和方法 - Google Patents

S-抗原转运抑制寡核苷酸聚合物和方法 Download PDF

Info

Publication number
CN113286803A
CN113286803A CN201980088039.4A CN201980088039A CN113286803A CN 113286803 A CN113286803 A CN 113286803A CN 201980088039 A CN201980088039 A CN 201980088039A CN 113286803 A CN113286803 A CN 113286803A
Authority
CN
China
Prior art keywords
complex
modified oligonucleotide
units
sequence
unit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980088039.4A
Other languages
English (en)
Chinese (zh)
Inventor
莱昂尼德·贝格尔曼
拉杰德拉·潘迪
维维克·库玛·拉贾万希
大卫·伯纳德·史密斯
劳伦斯·M·布拉特
洪劲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arigos Treatment Co
Original Assignee
Arigos Treatment Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arigos Treatment Co filed Critical Arigos Treatment Co
Publication of CN113286803A publication Critical patent/CN113286803A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/319—Chemical structure of the backbone linked by 2'-5' linkages, i.e. having a free 3'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525—MOE, methoxyethoxy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3527—Other alkyl chain
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3535—Nitrogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
CN201980088039.4A 2018-11-08 2019-11-07 S-抗原转运抑制寡核苷酸聚合物和方法 Pending CN113286803A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862757632P 2018-11-08 2018-11-08
US62/757,632 2018-11-08
US201962855323P 2019-05-31 2019-05-31
US62/855,323 2019-05-31
US201962907845P 2019-09-30 2019-09-30
US62/907,845 2019-09-30
PCT/US2019/060283 WO2020097342A1 (en) 2018-11-08 2019-11-07 S-antigen transport inhibiting oligonucleotide polymers and methods

Publications (1)

Publication Number Publication Date
CN113286803A true CN113286803A (zh) 2021-08-20

Family

ID=70551410

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980088039.4A Pending CN113286803A (zh) 2018-11-08 2019-11-07 S-抗原转运抑制寡核苷酸聚合物和方法

Country Status (18)

Country Link
US (1) US20200147124A1 (https=)
EP (1) EP3853240A4 (https=)
JP (1) JP2022512975A (https=)
KR (1) KR20210090217A (https=)
CN (1) CN113286803A (https=)
AU (1) AU2019376079A1 (https=)
BR (1) BR112021008539A2 (https=)
CA (1) CA3117163A1 (https=)
CL (1) CL2021001202A1 (https=)
CO (1) CO2021005762A2 (https=)
IL (1) IL282640A (https=)
MA (1) MA53674A (https=)
MX (1) MX2021005357A (https=)
PE (1) PE20211783A1 (https=)
PH (1) PH12021551007A1 (https=)
SG (1) SG11202104636XA (https=)
TW (1) TW202031267A (https=)
WO (1) WO2020097342A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114230624A (zh) * 2021-12-22 2022-03-25 上海兆维科技发展有限公司 一种核苷二聚体亚膦酰胺的合成方法
CN117534717A (zh) * 2024-01-09 2024-02-09 凯莱英生命科学技术(天津)有限公司 5′-(e)-乙烯基磷酸酯的合成方法
WO2024212918A1 (zh) * 2023-04-14 2024-10-17 苏州炫景生物科技有限公司 抑制c3基因表达的化合物、药物组合物及其用途
CN119569802A (zh) * 2025-02-06 2025-03-07 北京安龙生物医药有限公司 修饰寡核苷酸的化合物、其制备方法和应用

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
US20200385713A1 (en) * 2019-01-22 2020-12-10 Korro Bio, Inc. Rna-editing oligonucleotides and uses thereof
AU2020260105A1 (en) 2019-04-17 2021-11-04 Aligos Therapeutics, Inc. Bicyclic and tricyclic compounds
SG11202112741XA (en) 2019-05-31 2021-12-30 Aligos Therapeutics Inc Modified gapmer oligonucleotides and methods of use
AU2020289537A1 (en) 2019-06-06 2021-11-25 Aligos Therapeutics, Inc. Heterocyclic compounds
US20220281911A1 (en) * 2019-08-19 2022-09-08 Mina Therapeutics Limited Oligonucleotide conjugate compositions and methods of use
IL291251B1 (en) * 2019-09-10 2026-02-01 Daiichi Sankyo Co Ltd Oligonucleotide-galnac conjugate for targeted delivery to the liver and method for its production
US20210189392A1 (en) * 2019-12-12 2021-06-24 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
PE20221578A1 (es) 2020-03-06 2022-10-06 Aligos Therapeutics Inc Moleculas de acido nucleico interferente corto (sina, por sus siglas en ingles) modificadas y usos de estas
JP2023534557A (ja) * 2020-07-23 2023-08-09 エフ． ホフマン－ラ ロシュ アーゲー Ｒｎａ結合タンパク質部位を標的とするオリゴヌクレオチド
AU2021318943A1 (en) * 2020-07-27 2023-03-02 Aligos Therapeutics, Inc. HBV binding oligonucleotides and methods of use
EP4229062A4 (en) 2020-10-15 2024-10-30 Aligos Therapeutics, Inc. Bicyclic compounds
JP2023548031A (ja) 2020-10-21 2023-11-15 アリゴス セラピューティクス インコーポレイテッド 二環式化合物
WO2022109129A1 (en) * 2020-11-20 2022-05-27 Aligos Therapeutics, Inc. Conjugates of s-antigen transport inhibiting oligonucleotide polymers having enhanced liver targeting
EP4251625A4 (en) 2020-11-24 2024-10-09 Aligos Therapeutics, Inc. Tricyclic compounds
TW202245809A (zh) 2020-12-18 2022-12-01 美商詹森藥物公司 用於治療b型肝炎病毒感染之組合療法
WO2022152869A1 (en) 2021-01-15 2022-07-21 Janssen Sciences Ireland Unlimited Company Use of oligonucleotides for individuals with hepatic impairment
CA3204340A1 (en) * 2021-01-30 2022-08-04 Ahmad Ali MORTAZAVI Conjugated oligonucleotide compounds, methods of making and uses thereof
JP2024504504A (ja) * 2021-01-30 2024-01-31 イー セラピューティクス パブリック リミテッド カンパニー コンジュゲートオリゴヌクレオチド化合物、その作製方法及び使用
WO2022162157A1 (en) * 2021-01-30 2022-08-04 E-Therapeutics Plc Conjugated oligonucleotide compounds, methods of making and uses thereof
CN115850358B (zh) * 2021-03-08 2026-04-24 南京吉迈生物技术有限公司 GalNAc簇亚磷酰胺和靶向治疗性核苷
EP4349986A4 (en) * 2021-05-25 2025-11-19 Univ Nat Corp Tokyo Medical & Dental HETERONUCLEIC ACID WITH A CONTENT OF ?????? OR ????
US11957683B2 (en) 2021-06-18 2024-04-16 Aligos Therapeutics, Inc. Bicyclic compounds
JP2024527380A (ja) 2021-07-09 2024-07-24 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー３）、リミテッド 腎機能障害を有する個体へのオリゴヌクレオチドの使用
US20250243491A1 (en) 2021-09-01 2025-07-31 Aligos Therapeutics, Inc. Pnpla3-targeting short interfering rna (sirna) molecules and uses thereof
EP4399217A2 (en) 2021-09-08 2024-07-17 Aligos Therapeutics, Inc. Modified short interfering nucleic acid (sina) molecules and uses thereof
CN118234862A (zh) 2021-09-08 2024-06-21 阿利戈斯治疗公司 经修饰的短干扰核酸分子(siNA)及其用途
KR20240158340A (ko) 2022-03-17 2024-11-04 알리고스 테라퓨틱스 인코포레이티드 변형 갭머 올리고머 및 이의 사용 방법
EP4511374A4 (en) 2022-04-20 2026-04-08 Aligos Therapeutics Inc BICYCLE COMPOUNDS
WO2023222858A1 (en) * 2022-05-18 2023-11-23 F. Hoffmann-La Roche Ag Improved oligonucleotides targeting rna binding protein sites
WO2024182446A2 (en) 2023-02-28 2024-09-06 Aligos Therapeutics, Inc. Pnpla3-targeting short interfering rna (sirna) molecules and uses thereof
US20240352464A1 (en) 2023-03-07 2024-10-24 Aligos Therapeutics, Inc. Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof
WO2025143262A1 (ja) * 2023-12-28 2025-07-03 日産化学株式会社 カルバモイルエチル修飾を含有する二本鎖ｒｎａ
US20250368996A1 (en) 2024-05-14 2025-12-04 Aligos Therapeutics, Inc. Modified antisense oligonucleotides for treating hepatitis b virus
US20250382618A1 (en) * 2024-06-14 2025-12-18 Aligos Therapeutics, Inc. Methods and compositions for inhibiting virus

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006043521A1 (ja) * 2004-10-19 2006-04-27 Nippon Shinyaku Co., Ltd. ホスホロチオエート結合を有する光学活性なオリゴ核酸化合物
CN101084232A (zh) * 2004-10-19 2007-12-05 里普利科股份有限公司 抗病毒寡核苷酸
CN102766630A (zh) * 2006-01-27 2012-11-07 Isis制药公司 6-修饰的双环核酸类似物
US20130309201A1 (en) * 2012-05-18 2013-11-21 Replicor Inc. Oligonucleotide chelate complex - polypeptide compositions and methods
WO2016004525A1 (en) * 2014-07-10 2016-01-14 Replicor Inc. Methods for the treatment of hepatitis b and hepatitis d virus infections
WO2018053185A1 (en) * 2016-09-14 2018-03-22 Alios Biopharma, Inc. Modified oligonucleotides and methods of use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013003875B1 (pt) * 2010-08-20 2021-10-05 Replicor Inc Composições farmacêuticas compreendendo complexo de quelato de oligonucleotídeo, formulação de oligonucleotídeo, e usos

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006043521A1 (ja) * 2004-10-19 2006-04-27 Nippon Shinyaku Co., Ltd. ホスホロチオエート結合を有する光学活性なオリゴ核酸化合物
CN101084232A (zh) * 2004-10-19 2007-12-05 里普利科股份有限公司 抗病毒寡核苷酸
CN102766630A (zh) * 2006-01-27 2012-11-07 Isis制药公司 6-修饰的双环核酸类似物
US20130309201A1 (en) * 2012-05-18 2013-11-21 Replicor Inc. Oligonucleotide chelate complex - polypeptide compositions and methods
WO2016004525A1 (en) * 2014-07-10 2016-01-14 Replicor Inc. Methods for the treatment of hepatitis b and hepatitis d virus infections
WO2018053185A1 (en) * 2016-09-14 2018-03-22 Alios Biopharma, Inc. Modified oligonucleotides and methods of use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MARIA J. BUZON ET AL.: "Nucleic Acid Polymers Are Active against Hepatitis Delta Virus Infection In Vitro", 《 JOURNAL OF VIROLOGY》, vol. 85, no. 18, pages 9646 *
REPLICOR INC ET AL.: ""Nucleic acid polymers: Broad spectrum antiviral activity, antiviral mechanisms and optimization for the treatment of hepatitis B and hepatitis D infection"", 《ANTIVIRAL RESEARCH》, vol. 133, pages 32 - 40, XP029727986, DOI: 10.1016/j.antiviral.2016.07.004 *
ROEHL, INGO ET AL.: ""Nucleic Acid Polymers with Accelerated Plasma and Tissue Clearance for Chronic Hepatitis B Therapy"", 《NUCLEIC ACIDS》, vol. 8, pages 1 - 12, XP055707785, DOI: 10.1016/j.omtn.2017.04.019 *
VASULINGA T. RAVIKUMAR ET AL.: "Development of 2\'-O-Methoxyethyl Phosphorothioate Oligonucleotides as Antisense Drugs under Stereochemical Control", 《ORGANIC PROCESS RESEARCH & DEVELOPMENT》, vol. 6, 31 December 2002 (2002-12-31), pages 798 - 806, XP055712394, DOI: 10.1021/op020061c *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114230624A (zh) * 2021-12-22 2022-03-25 上海兆维科技发展有限公司 一种核苷二聚体亚膦酰胺的合成方法
WO2024212918A1 (zh) * 2023-04-14 2024-10-17 苏州炫景生物科技有限公司 抑制c3基因表达的化合物、药物组合物及其用途
CN117534717A (zh) * 2024-01-09 2024-02-09 凯莱英生命科学技术(天津)有限公司 5′-(e)-乙烯基磷酸酯的合成方法
CN119569802A (zh) * 2025-02-06 2025-03-07 北京安龙生物医药有限公司 修饰寡核苷酸的化合物、其制备方法和应用
CN119569802B (zh) * 2025-02-06 2025-06-13 北京安龙生物医药有限公司 修饰寡核苷酸的化合物、其制备方法和应用

Also Published As

Publication number Publication date
PH12021551007A1 (en) 2021-10-04
AU2019376079A1 (en) 2021-05-27
TW202031267A (zh) 2020-09-01
US20200147124A1 (en) 2020-05-14
CO2021005762A2 (es) 2021-07-30
BR112021008539A2 (pt) 2021-08-03
SG11202104636XA (en) 2021-06-29
EP3853240A4 (en) 2022-11-30
WO2020097342A1 (en) 2020-05-14
JP2022512975A (ja) 2022-02-07
CA3117163A1 (en) 2020-05-14
IL282640A (en) 2021-06-30
MX2021005357A (es) 2021-06-30
EP3853240A1 (en) 2021-07-28
PE20211783A1 (es) 2021-09-08
CL2021001202A1 (es) 2021-12-17
MA53674A (fr) 2021-07-28
KR20210090217A (ko) 2021-07-19

Similar Documents

Publication Publication Date Title
CN113286803A (zh) S-抗原转运抑制寡核苷酸聚合物和方法
JP7792371B2 (ja) ＧａｌＮＡｃ誘導体
CN106795197B (zh) 改性寡核苷酸及其制备方法
EP2370451B1 (en) Method for the synthesis of phosphorus atom modified nucleic acids
US20210189392A1 (en) S-antigen transport inhibiting oligonucleotide polymers and methods
US11166976B2 (en) S-antigen transport inhibiting oligonucleotide polymers and methods
RU2740501C2 (ru) МОДИФИЦИРОВАННЫЕ ОЛИГОНУКЛЕОТИДЫ, АКТИВИРУЮЩИЕ РНКазу Н
US20040132684A1 (en) Polymeric nucleoside prodrugs
TWI769177B (zh) 經修飾之寡核苷酸及使用方法
CN115176009A (zh) 用于靶向pd-l1的方法和组合物
CN116615542A (zh) 寡核苷酸的全身递送
TW202444908A (zh) ５＇－膦酸酯修飾的核苷類似物及其製備的寡核苷酸
CN115298192A (zh) 4′-o-亚甲基膦酸酯核酸及其类似物
WO2024002007A1 (zh) 含有可降低脱靶毒性的核苷酸类似物的双链rna
EA045960B1 (ru) Олигонуклеотидные полимеры и способы для ингибирования транспорта s-антигена
CN120904263B (zh) 具有增加寡核苷酸体内稳定性的2'核糖修饰的核苷酸化合物及其合成方法与应用
US20110282044A1 (en) Process for synthesizing oligonucleotide phosphate derivatives
OA20592A (en) S-antigen transport inhibiting oligonucleotide polymers and methods
TW202604551A (zh) 用於治療ｂ型肝炎病毒之經修飾之反義寡核苷酸
HK40077738A (en) Modified oligonucleotides and methods for their synthesis
HK40036011A (en) Galnac derivatives

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20210820

WD01 Invention patent application deemed withdrawn after publication